The impact of vaccines on pneumonia: key lessons from Haemophilus influenzae type b conjugate vaccines.
This article explores key lessons learned from vaccination with Haemophilus influenzae type b (Hib) conjugate vaccine and how these lessons may provide insight into the impact of emergent pneumococcal vaccines against pneumonia. The worldwide value of Hib vaccination for reducing Hib disease burden and carriage is reviewed. Using comparisons of data for pneumococcus versus Hib, the article concludes that epidemiological and biological differences between these pathogens will complicate efforts to use results from the Hib vaccine experience to predict outcomes following pneumococcal conjugate vaccine introduction.
Gessner
Bradford D
BD
Agence de Médecine Préventive, Institut Pasteur, 28 rue du Doctor Roux, F-75724 Paris, France. BradGessner@compuserve.com
Adegbola
Richard A
RA
D016667:Bacterial Capsules / Q000627:therapeutic use; D006192:Haemophilus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000627:therapeutic use*; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D017589:Immunization Programs / Q000458:organization & administration; D018410:Pneumonia, Bacterial / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D018074:Vaccines, Conjugate / Q000276:immunology / Q000627:therapeutic use*
D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D018074:Vaccines, Conjugate